<code id='3B7D5C4ED7'></code><style id='3B7D5C4ED7'></style>
    • <acronym id='3B7D5C4ED7'></acronym>
      <center id='3B7D5C4ED7'><center id='3B7D5C4ED7'><tfoot id='3B7D5C4ED7'></tfoot></center><abbr id='3B7D5C4ED7'><dir id='3B7D5C4ED7'><tfoot id='3B7D5C4ED7'></tfoot><noframes id='3B7D5C4ED7'>

    • <optgroup id='3B7D5C4ED7'><strike id='3B7D5C4ED7'><sup id='3B7D5C4ED7'></sup></strike><code id='3B7D5C4ED7'></code></optgroup>
        1. <b id='3B7D5C4ED7'><label id='3B7D5C4ED7'><select id='3B7D5C4ED7'><dt id='3B7D5C4ED7'><span id='3B7D5C4ED7'></span></dt></select></label></b><u id='3B7D5C4ED7'></u>
          <i id='3B7D5C4ED7'><strike id='3B7D5C4ED7'><tt id='3B7D5C4ED7'><pre id='3B7D5C4ED7'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:234
          Blood corpuscles in clot
          Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success. David Gregory & Debbie Marshall/Wellcome Images

          Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success.

          LimFlow recently snagged Food and Drug Administration approval for its surgical system that uses a stent to connect a blocked artery to an open vein, thus allowing blood to flow through and heal injuries. The tool is meant only for patients with a severe form of peripheral artery disease, and who have already tried more conservative options.

          advertisement

          Dan Rose, CEO of LimFlow, previously told STAT that his mission is to fight the amputation epidemic in the United States, which disproportionately impacts Black patients. Experts cautioned to STAT that expanding screenings to catch the disease early is still the most important measure.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          Readout Newsletter: Parkinson's study, Gilead, CG Oncology
          Readout Newsletter: Parkinson's study, Gilead, CG Oncology

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Was Amgen transparent enough on FDA's concern on cancer drug?

          MarkJ.Terrill/APAmidthestunningrebukeAmgensufferedatthehandsoftheU.S.FoodandDrugAdministrationthiswe